SG11202003273PA - Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same - Google Patents
Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising sameInfo
- Publication number
- SG11202003273PA SG11202003273PA SG11202003273PA SG11202003273PA SG11202003273PA SG 11202003273P A SG11202003273P A SG 11202003273PA SG 11202003273P A SG11202003273P A SG 11202003273PA SG 11202003273P A SG11202003273P A SG 11202003273PA SG 11202003273P A SG11202003273P A SG 11202003273PA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- same
- pharmaceutical composition
- cancer treatment
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170136564A KR101973060B1 (en) | 2017-10-20 | 2017-10-20 | Antibody against cd3 and pharmaceutical composition for treating cancer comprising the same |
| PCT/KR2018/012492 WO2019078697A2 (en) | 2017-10-20 | 2018-10-22 | Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003273PA true SG11202003273PA (en) | 2020-05-28 |
Family
ID=66173409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003273PA SG11202003273PA (en) | 2017-10-20 | 2018-10-22 | Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11498965B2 (en) |
| EP (1) | EP3699192A4 (en) |
| JP (1) | JP7024072B2 (en) |
| KR (1) | KR101973060B1 (en) |
| CN (1) | CN111315779B (en) |
| AU (1) | AU2018353787B2 (en) |
| BR (1) | BR112020007770A2 (en) |
| CA (1) | CA3077007C (en) |
| EA (1) | EA202090944A1 (en) |
| IL (1) | IL274007A (en) |
| MX (1) | MX2020003947A (en) |
| SG (1) | SG11202003273PA (en) |
| WO (1) | WO2019078697A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020236797A1 (en) * | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
| TW202216784A (en) * | 2020-09-29 | 2022-05-01 | 大陸商信達生物製藥（蘇州）有限公司 | Anti-cd3 antibody and the use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003243138A1 (en) | 2002-03-26 | 2003-10-13 | Trubion Pharmaceuticals, Inc. | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb |
| EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| SG10201509588TA (en) * | 2011-05-21 | 2015-12-30 | Macrogenics Inc | CD3-Binding Molecules Capable Of Binding To Human And Non-Human CD3 |
| JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
| KR102363220B1 (en) | 2013-07-05 | 2022-02-15 | 젠맵 에이/에스 | Humanized or chimeric cd3 antibodies |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| WO2015095392A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| EP3164417A1 (en) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| JP6951826B2 (en) * | 2016-02-04 | 2021-10-20 | ザ スクリプス リサーチ インスティテュート | Humanized anti-CD3 antibody, its complex, and its use |
| KR102329635B1 (en) | 2017-04-24 | 2021-11-22 | 재단법인 목암생명과학연구소 | Bispecific antibodies that bind HER3 and CD3 |
-
2017
- 2017-10-20 KR KR1020170136564A patent/KR101973060B1/en active IP Right Grant
-
2018
- 2018-10-22 CA CA3077007A patent/CA3077007C/en active Active
- 2018-10-22 BR BR112020007770-4A patent/BR112020007770A2/en unknown
- 2018-10-22 CN CN201880068391.7A patent/CN111315779B/en active Active
- 2018-10-22 EP EP18867685.2A patent/EP3699192A4/en active Pending
- 2018-10-22 JP JP2020521940A patent/JP7024072B2/en active Active
- 2018-10-22 AU AU2018353787A patent/AU2018353787B2/en active Active
- 2018-10-22 SG SG11202003273PA patent/SG11202003273PA/en unknown
- 2018-10-22 EA EA202090944A patent/EA202090944A1/en unknown
- 2018-10-22 MX MX2020003947A patent/MX2020003947A/en unknown
- 2018-10-22 WO PCT/KR2018/012492 patent/WO2019078697A2/en unknown
- 2018-10-22 US US16/754,431 patent/US11498965B2/en active Active
-
2020
- 2020-04-16 IL IL274007A patent/IL274007A/en unknown
-
2022
- 2022-10-03 US US17/958,995 patent/US20230192851A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018353787B2 (en) | 2022-02-24 |
| KR101973060B1 (en) | 2019-04-26 |
| BR112020007770A2 (en) | 2020-10-20 |
| CA3077007A1 (en) | 2019-04-25 |
| MX2020003947A (en) | 2020-08-03 |
| CA3077007C (en) | 2023-04-18 |
| CN111315779B (en) | 2024-06-21 |
| US20200317779A1 (en) | 2020-10-08 |
| EA202090944A1 (en) | 2020-07-16 |
| IL274007A (en) | 2020-05-31 |
| WO2019078697A2 (en) | 2019-04-25 |
| US11498965B2 (en) | 2022-11-15 |
| EP3699192A2 (en) | 2020-08-26 |
| CN111315779A (en) | 2020-06-19 |
| AU2018353787A1 (en) | 2020-05-21 |
| US20230192851A1 (en) | 2023-06-22 |
| WO2019078697A8 (en) | 2020-04-09 |
| WO2019078697A3 (en) | 2019-07-04 |
| JP7024072B2 (en) | 2022-02-22 |
| EP3699192A4 (en) | 2021-10-20 |
| JP2021501571A (en) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3616720T3 (en) | Pharmaceutical composition for cancer treatment | |
| IL265541B2 (en) | Bispecific antibodies and compositions comprising thereof for treating cancer | |
| HK1257056A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| EP3524268A4 (en) | Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers | |
| HK1247848A1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
| IL267567B2 (en) | Anti-cd3 antibody for use in the treatment or prophylaxis of cancer, and molecules containing said antibody | |
| IL260474B (en) | Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment | |
| IL266486A (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| EP3502142A4 (en) | Bispecific antibody and antibody conjugate for tumour therapy and use thereof | |
| IL274008A (en) | Anti-msln antibody and pharmaceutical composition comprising same for cancer treatment | |
| IL275525A (en) | Pharmaceutical composition for the treatment of cancer | |
| IL272669A (en) | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer | |
| EP3708173C0 (en) | Pharmaceutical composition comprising mirna-3140 for use in treating cancer | |
| ZA201802618B (en) | Anti-cd43 antibody and use thereof for cancer treatment | |
| IL274007A (en) | Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same | |
| PT3290051T (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| EP3563856A4 (en) | Pharmaceutical composition for treating cancer and use thereof | |
| EP3647325A4 (en) | Pharmaceutical composition comprising pcsk-9 antibody and use thereof | |
| EP3406626A4 (en) | Peptide for cancer treatment and pharmaceutical composition containing same | |
| IL249860A0 (en) | Pharmaceutical compositions, methods for their preparation and their use in the treatment of cancer | |
| EP3372233A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| EP3441465A4 (en) | Cancer treatment pharmaceutical composition using anti-mct5 antibody | |
| GB201718925D0 (en) | Pharmaceutical composition suitable for gastric cancer treatment and/or prevention | |
| EP3498284A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer |